Spots Global Cancer Trial Database for durvalumab (medi4736)
Every month we try and update this database with for durvalumab (medi4736) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | NCT03833440 | Non-small Cell ... | Durvalumab (MED... Monalizumab (IP... Oleclumab (MEDI... Ceralasertib (A... DOCETAXEL Savolitinib | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. | |
| Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | NCT03003962 | Non Small Cell ... | Durvalumab (MED... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | NCT03833440 | Non-small Cell ... | Durvalumab (MED... Monalizumab (IP... Oleclumab (MEDI... Ceralasertib (A... DOCETAXEL Savolitinib | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | NCT03122496 | Metastatic Anap... | durvalumab tremelimumab Stereotactic Bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer | NCT03528694 | Non-muscle-inva... | Durvalumab (MED... Bacillus Calmet... | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC | NCT03732677 | Muscle Invasive... | Durvalumab Cisplatin Gemcitabine | 18 Years - 130 Years | AstraZeneca | |
| Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | NCT03122496 | Metastatic Anap... | durvalumab tremelimumab Stereotactic Bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | NCT03003962 | Non Small Cell ... | Durvalumab (MED... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | NCT03833440 | Non-small Cell ... | Durvalumab (MED... Monalizumab (IP... Oleclumab (MEDI... Ceralasertib (A... DOCETAXEL Savolitinib | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin | NCT04960709 | Muscle Invasive... | Durvalumab Tremelimumab Enfortumab Vedo... Radical Cystect... | 18 Years - 130 Years | AstraZeneca | |
| Synergism of Immunomodulation and Tumor Ablation | NCT03101475 | Colorectal Canc... Liver Metastase... | Durvalumab (MED... Tremelimumab Sterotactic bod... Radiofrequency ... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
